세계의 자궁내막암 치료 시장

Global Endometrial Cancer Treatment Market to Reach US$46.3 Billion by 2030

The global market for Endometrial Cancer Treatment estimated at US$34.6 Billion in the year 2024, is expected to reach US$46.3 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$31.3 Billion by the end of the analysis period. Growth in the Hormone Therapy segment is estimated at 5.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$9.5 Billion While China is Forecast to Grow at 4.9% CAGR

The Endometrial Cancer Treatment market in the U.S. is estimated at US$9.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$7.4 Billion by the year 2030 trailing a CAGR of 4.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.6% and 4.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global Endometrial Cancer Treatment Market - Key Trends and Drivers Summarized

How Is Endometrial Cancer Treatment Revolutionizing Women's Health and Oncology?

Endometrial cancer treatment is revolutionizing women's health and oncology by providing increasingly effective, personalized, and less invasive options for managing one of the most common gynecological cancers. Endometrial cancer, which affects the lining of the uterus, is typically diagnosed in postmenopausal women and has seen rising incidence rates due to factors like obesity and aging populations. Advances in treatment are significantly improving survival rates and quality of life for patients. From surgery and radiation to hormone therapy and targeted treatments, the landscape of endometrial cancer care is evolving rapidly. Surgical techniques, particularly minimally invasive procedures like laparoscopic and robotic-assisted surgery, allow for precise removal of cancerous tissues with shorter recovery times and fewer complications. Additionally, the advent of targeted therapies and immunotherapy is offering new hope for patients with advanced or recurrent endometrial cancer, tailoring treatment to the specific genetic makeup of their tumors. This shift towards personalized medicine is making endometrial cancer treatment more effective and patient-centered, transforming outcomes and setting new standards in oncology.

What Innovations Are Enhancing the Treatment of Endometrial Cancer?

Innovations in the treatment of endometrial cancer are enhancing care through advancements in surgical techniques, targeted therapies, and genetic testing. One of the most significant developments is the improvement in minimally invasive surgical methods, such as laparoscopic and robotic-assisted surgeries, which allow for the precise removal of tumors with less damage to surrounding tissues. These techniques reduce postoperative pain, shorten hospital stays, and lead to quicker recoveries, making surgery a less daunting option for many patients. Another key innovation is the introduction of targeted therapies, which attack specific molecules involved in cancer growth and progression. For instance, therapies targeting the PI3K/AKT/mTOR pathway, commonly altered in endometrial cancer, are showing promise in clinical trials. These treatments offer a more personalized approach, particularly for patients with advanced disease or those who do not respond well to conventional therapies. Additionally, immunotherapy is emerging as a powerful tool in treating endometrial cancer, harnessing the body's immune system to fight cancer cells more effectively. Genetic testing and molecular profiling of tumors are also playing a critical role in treatment planning, allowing oncologists to identify specific mutations and select therapies that are most likely to be effective for individual patients. These innovations are making endometrial cancer treatment more precise, less invasive, and better tailored to the needs of each patient, significantly improving outcomes and quality of life.

How Does Endometrial Cancer Treatment Impact Patient Outcomes and Quality of Life?

Endometrial cancer treatment has a profound impact on patient outcomes and quality of life by offering more effective and less invasive options that lead to better long-term health and well-being. Early-stage endometrial cancer is often highly treatable, with surgery being the primary mode of treatment. Advances in surgical techniques, such as laparoscopic and robotic-assisted procedures, minimize the physical and emotional toll on patients, leading to faster recoveries and fewer complications compared to traditional open surgeries. For patients with more advanced or recurrent cancer, the introduction of targeted therapies and immunotherapy is improving survival rates and offering new hope where options were previously limited. These treatments are not only extending life but also improving its quality by reducing the side effects associated with more aggressive treatments like chemotherapy and radiation. Hormone therapy, often used in cases where surgery is not an option, offers another less invasive treatment pathway that can effectively manage the disease while preserving fertility in younger women. By focusing on the specific needs and circumstances of each patient, modern endometrial cancer treatment is enhancing the overall experience, ensuring that patients not only live longer but also maintain a higher quality of life throughout and after their treatment journey.

What Trends Are Driving Growth in Endometrial Cancer Treatment?

Several trends are driving growth in endometrial cancer treatment, including the increasing prevalence of the disease, advancements in personalized medicine, and the growing focus on minimally invasive treatment options. The rising incidence of endometrial cancer, driven by factors such as aging populations and the obesity epidemic, is leading to greater demand for effective treatment options. This has spurred investment in research and development, resulting in new therapies and surgical techniques that are more effective and less burdensome for patients. The shift towards personalized medicine is also a significant driver, as genetic testing and molecular profiling of tumors allow for more tailored treatment strategies. This approach not only improves the effectiveness of treatment but also reduces unnecessary side effects, making it more appealing to patients and healthcare providers alike. Additionally, there is a growing emphasis on minimally invasive treatments, driven by patient demand for options that offer quicker recovery times and fewer complications. Innovations in robotic surgery and targeted therapies are making these options more widely available and effective. Finally, the increasing use of immunotherapy in oncology is expanding treatment possibilities for endometrial cancer, particularly for patients with advanced or resistant forms of the disease. These trends are reshaping the landscape of endometrial cancer treatment, offering new hope and improved outcomes for patients while driving growth in the market for innovative therapies and technologies.

SCOPE OF STUDY:

The report analyzes the Endometrial Cancer Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Chemotherapy, Hormone therapy)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 38 Featured) -

• Curasight A/S
• Dheeraj Bojwani Consultants
• Erasmus MC
• F. Hoffmann-La Roche AG
• Florida Cancer Specialists
• ITM Isotopen Technologien Munchen AG
• Merck & Co., Inc.
• Premium Europe
• Providence Therapeutics Holdings Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Endometrial Cancer Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • Global Economic Update
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Incidence of Endometrial Cancer Driving Demand for Effective Treatments
  • Advancements in Targeted Therapies and Immunotherapy Enhancing Treatment Efficacy
  • Growing Adoption of Minimally Invasive Surgeries for Cancer Treatment
  • Development of Novel Chemotherapeutic Agents and Drug Combinations
  • Integration of Advanced Imaging Technologies for Early Diagnosis and Treatment Planning
  • Adoption of Digital Health Records Improving Patient Management
  • Future Directions: Nanotechnology and Its Potential in Drug Delivery Systems for Cancer
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Endometrial Cancer Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 3: World 15-Year Perspective for Endometrial Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 6: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Hormone therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Hormone therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 9: World 15-Year Perspective for Hormone therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 10: World Endometrial Cancer Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Endometrial Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 11: USA Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 12: USA Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: USA 15-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 14: Canada Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 15: Canada Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: Canada 15-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2015, 2025 & 2030
• JAPAN
  • Endometrial Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 17: Japan Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 18: Japan Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: Japan 15-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2015, 2025 & 2030
• CHINA
  • Endometrial Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 20: China Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 21: China Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: China 15-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2015, 2025 & 2030
• EUROPE
  • Endometrial Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 23: Europe Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: Europe Historic Review for Endometrial Cancer Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: Europe 15-Year Perspective for Endometrial Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 26: Europe Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: Europe Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: Europe 15-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2015, 2025 & 2030
• FRANCE
  • Endometrial Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 29: France Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: France Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: France 15-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2015, 2025 & 2030
• GERMANY
  • Endometrial Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 32: Germany Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Germany Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: Germany 15-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 35: Italy Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Italy Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: Italy 15-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Endometrial Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 38: UK Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: UK Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: UK 15-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 41: Rest of Europe Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Rest of Europe Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Rest of Europe 15-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Endometrial Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 44: Asia-Pacific Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Asia-Pacific Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Asia-Pacific 15-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2015, 2025 & 2030
• REST OF WORLD
  • TABLE 47: Rest of World Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Rest of World Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Rest of World 15-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2015, 2025 & 2030

IV. COMPETITION